Japan’s Takeda allows Sun Pharma, Cipla to market gastro drug in India

Mumbai, Jun 21 (IANS): Japan's Takeda Pharmaceutical gave India's Sun Pharmaceutical and Cipla the rights to commercialise the gastrointestinal drug Vonoprazan in the country.

The drug, which is sold in the form of tablets under the brand name 'Voltapraz', blocks a key step in the production of stomach acid, Sun Pharma said on Friday.

Takeda has granted both drugmakers non-exclusive patent licensing rights for the drug.

Cipla and Sun Pharma will independently commercialise the drug in India under their respective brands.

Vonoprazan (oral tablets) is a novel potassium-competitive acid blocker (P-CAB), used for the treatment of Gastroesophageal Reflux Disease (GERD).

Vonoprazan is also used in treating disorders such as erosive oesophagitis, gastric ulcer, duodenal ulcer, peptic ulcer, gastro-oesophageal reflux, reflux oesophagitis and Helicobacter pylori eradication, according to a Cipla statement.




Top Stories

Leave a Comment

Title: Japan’s Takeda allows Sun Pharma, Cipla to market gastro drug in India

You have 2000 characters left.


Please write your correct name and email address. Kindly do not post any personal, abusive, defamatory, infringing, obscene, indecent, discriminatory or unlawful or similar comments. Daijiworld.com will not be responsible for any defamatory message posted under this article.

Please note that sending false messages to insult, defame, intimidate, mislead or deceive people or to intentionally cause public disorder is punishable under law. It is obligatory on Daijiworld to provide the IP address and other details of senders of such comments, to the authority concerned upon request.

Hence, sending offensive comments using daijiworld will be purely at your own risk, and in no way will Daijiworld.com be held responsible.